Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GDF-15 monoclonal antibody CTL-002

A humanized, hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody directed against growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor; PDF; placental bone morphogenetic protein; PLAB), with potential antineoplastic activity. Upon administration, anti-GDF-15 monoclonal antibody CTL-002 specifically targets, binds to and inhibits the activity of GDF-15, which may include its inhibition of lymphocyte function-associated antigen 1 (LFA-1) activation on CD8+ T cells. This may restore immune cell infiltration into the tumor, leading to tumor cell killing and inhibition of tumor cell proliferation. GDF-15, a divergent member of the transforming growth factor-beta (TGF-beta) superfamily of cytokines, is upregulated in tissue injuries and also secreted by various tumors. It has been linked to immunosuppression in the tumor microenvironment (TME) and is associated with drug resistance and poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:CTL 002
CTL-002
CTL002
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search